OXB Showcases Innovations at 28th Annual ASGCT Meeting
OXB Showcases Innovations at 28th Annual ASGCT Meeting
OXB (LSE: OXB), a leader in the development and manufacturing of cell and gene therapies, is thrilled to announce its participation in the prestigious 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). This significant event is set to occur from May 13 to May 17 at the renowned Ernest N. Morial Convention Center.
At ASGCT, OXB will exhibit in Booth #1611, giving delegates a unique opportunity to engage with our expert team specializing in viral vector technologies. Participants will discover our state-of-the-art capabilities in developing and manufacturing viral vectors, including lentiviral and AAV types, which are crucial to the advancement of gene therapies.
Highlighted Contributions to the ASGCT Program
OXB's influence at the ASGCT will extend beyond the exhibit floor, as we actively participate in the scientific program. The company will host an industry-sponsored symposium, in addition to presenting five posters and delivering two oral presentations.
Industry-Sponsored Symposium
One of the key highlights includes our symposium titled "Accelerate Time to Clinic: A Process and Analytics Platform Approach". This session will focus on innovative strategies to streamline the path from development to clinical application, featuring expert insights from Ify Iwuchukwu, PhD, the Vice President of Development Services. Join us on Tuesday, May 13, from 14:00 to 14:30 CDT in Room 391-392.
Poster Presentations
In addition to our symposium, we will unveil groundbreaking research through various poster presentations:
- The 3 Rs of Replication-Competent Lentivirus (RCL) Formation Risk: Real, Rare, or Artificial? - Presented by Dan Farley, PhD on Wednesday, May 14, 17:30-19:30 CDT, Hall I2.
- Enhancing Titers of Therapeutic Lentiviral Vectors using PKC Agonists - Presented by André Raposo, PhD on Wednesday, May 14, 17:30-19:30 CDT, Hall I2.
- Optimising the Production of the 4th Generation Lentiviral Vector (LV) TetraVecta™ System - Presented by Dan Farley, PhD on Wednesday, May 14, 17:30-19:30 CDT, Hall I2.
- The Impact of Individual Helper Genes on AAV Productivity - Presented by Katrina Costa-Grant on Thursday, May 15, 17:30-19:30 CDT, Hall I2.
- Evaluation of Salt-Tolerant Endonucleases for Lentiviral Vector Purification - Presented by Alice Oliveira Aguiar on Thursday, May 15, 17:30-19:30 CDT, Hall I2.
Oral Presentations to Highlight Cutting-Edge Research
As part of our commitment to advancing scientific knowledge, OXB will also deliver two significant oral presentations:
- Enhancing Upstream Processes for High-Yield, High-Quality AAV Vector Production - Presented by Dicky Gilmore on Friday, May 16, from 15:45 to 16:00 CDT, New Orleans Theater C.
- Diving Deeper: Using a SYBR Gold Capsid Ejection Assay - Presented by Michaela Duffy on Friday, May 16, from 17:00 to 17:15 CDT, Room 288-290.
Connecting with OXB at the Conference
For those attending the ASGCT meeting, OXB’s participation presents a perfect opportunity to explore new advancements in cell and gene therapy. We invite you to visit our booth and engage with our team about how our innovative processes and technologies can elevate your therapeutic development.
About OXB
Based in Oxford, UK, OXB (LSE: OXB) is a global leader in providing contract development and manufacturing organization (CDMO) services focused on cell and gene therapies. With over three decades of experience, OXB has pioneered the field of viral vectors, enabling clients to successfully deliver life-changing therapies to patients worldwide.
Our comprehensive range of services includes expertise in lentivirus, adeno-associated virus (AAV), and adenovirus vector production, along with robust quality assurance and regulatory expertise. We aim to facilitate our clients' journeys from early development to full commercialization, offering cutting-edge technologies like our TetraVecta™ 4th generation lentiviral vector system.
Frequently Asked Questions
What is OXB's role at the ASGCT 2025 Meeting?
OXB will exhibit and contribute to the scientific program with presentations and a symposium focused on advancing cell and gene therapies.
Who will be presenting at OXB's symposium?
Ify Iwuchukwu, PhD, will lead the symposium on accelerating clinical processes and analytics.
When and where will OXB's symposium take place?
The symposium is scheduled for Tuesday, May 13, from 14:00 to 14:30 CDT in Room 391-392.
How can attendees learn more about OXB's technologies?
Delegates can visit OXB at Booth #1611 to explore our services and engage with our experts.
What makes OXB a leader in cell and gene therapy?
With 30 years of experience, OXB specializes in viral vectors, boasting comprehensive capabilities that help facilitate the development of innovative therapies.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.